Activating mutations of KRAS are found in around 40% of CRC patients [3], RAS signaling triggers multiple downstream pathways, including RAF-MEK1-ERK1 pathway (also known as MAPK (mitogen activated protein kinase pathway) [4]. Here, MAP2K1 is linked to colorectal carcinoma.